The Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Meeting – Waters Corporation today announced the launch of the Xevo TQ Absolute XR IVD Mass Spectrometer, expanding its MassTrak™ IVD System portfolio of LC-MS/MS Systems with a solution that combines class-leading sensitivity and enhanced robustness for clinical applications. The new system builds on the industry-renowned step-change performance of the Xevo TQ Absolute IVD Mass Spectrometer, which established the benchmark for sensitivity among IVD-compliant tandem quadrupole mass spectrometers.
Developed for routine laboratory testing requiring IVD-compliant systems, the Xevo TQ Absolute XR IVD System delivers exceptional trace-level analytical performance in complex biological matrices. With up to five times greater sensitivity than other instruments in its class, the system enables lower limits of detection and reliable quantification of challenging analytes from smaller sample volumes. This enhanced sensitivity is critical for applications requiring accurate measurement at very low concentrations, such as low-level estradiol testing for women's health and hormone-related cancer assessment, and hair toxicology for detecting drugs of abuse and documenting long-term exposure.
"Waters' IVD Systems provide clinical diagnostic laboratories with highly precise and flexible solutions that help clinicians make informed decisions when every test matters," said Jianqing Bennett, Senior Vice President, Waters Advanced Diagnostics, Waters Corporation. "With the introduction of the Xevo TQ Absolute XR IVD System, Waters is delivering a new standard of sensitivity and robustness that can significantly reduce downtime and improve laboratory productivity. Waters is uniquely positioned to help clinical laboratories develop reliable methods for complex analytes and expand their testing capabilities to meet growing demand across women's health, cancer assessment, and toxicology applications."
Featuring the new StepWave™ XR Ion Guide, the Xevo TQ Absolute XR IVD System delivers improved robustness, enabling ion ratio consistency for up to six times longer compared with the Xevo TQ Absolute IVD System. This advancement gives laboratories greater confidence in consistent performance when analyzing complex clinical samples containing phospholipids, salts, and other matrix components.
Having the Xevo TQ Absolute XR IVD Systems in our laboratory is a major advancement for the company, The systems strengthen our analytical reliability, have the potential to greatly expand our substance testing capabilities, and improve operational efficiency. They deliver better signal stability and improved sensitivity, which is especially important when working close to decision cut-offs in complex matrices such as human hair. This gives us greater confidence in our results and provides additional assurance when measuring analytes at very low concentrations."
James Nutt, Head of Laboratory Operations, Cansford Laboratories
This new MassTrak LC-MS/MS IVD System includes the ACQUITY™ UPLC I-Class PLUS System with the Xevo TQ Absolute XR IVD Mass Spectrometer. The ACQUITY UPLC I-Class PLUS System is designed to deliver fast, accurate sample analysis that enhances mass spectrometer performance and simplifies the characterization of complex samples. Together, the integrated system delivers industry-leading sensitivity, enhanced robustness for complex sample matrices, and a user-friendly design that helps maximize laboratory uptime.
The MassTrak LC-MS/MS IVD System with the Xevo TQ Absolute XR Mass Spectrometer is available to order now.
Facts Only
* Waters Corporation announced the launch of the Xevo TQ Absolute XR IVD Mass Spectrometer.
* The system expands the MassTrak™ IVD System portfolio of LC-MS/MS Systems.
* The new system combines class-leading sensitivity and enhanced robustness for clinical applications.
* The Xevo TQ Absolute XR IVD System builds on the performance of the Xevo TQ Absolute IVD Mass Spectrometer.
* The system delivers up to five times greater sensitivity than other instruments in its class.
* The enhanced sensitivity allows for lower limits of detection and reliable quantification from smaller sample volumes.
* Applications mentioned include low-level estradiol testing, hormone-related cancer assessment, and hair toxicology.
* The StepWave™ XR Ion Guide delivers improved robustness, enabling ion ratio consistency for up to six times longer compared to the Xevo TQ Absolute IVD System.
* The system includes the ACQUITY™ UPLC I-Class PLUS System integrated with the mass spectrometer.
* The MassTrak LC-MS/MS IVD System with the Xevo TQ Absolute XR Mass Spectrometer is available to order.
Executive Summary
Waters Corporation announced the launch of the Xevo TQ Absolute XR IVD Mass Spectrometer, which expands its MassTrak™ IVD System portfolio of LC-MS/MS Systems. This new system combines high sensitivity and robustness for clinical applications, building upon the performance of the existing Xevo TQ Absolute IVD Mass Spectrometer. The system is designed for routine laboratory testing requiring IVD-compliant systems and provides exceptional trace-level analytical performance in complex biological matrices. It offers up to five times greater sensitivity than other instruments in its class, enabling lower limits of detection for analytes such as estradiol and hair toxicology.
The enhancement in robustness is delivered through the new StepWave™ XR Ion Guide, which allows for ion ratio consistency for up to six times longer compared to previous systems, improving performance when analyzing complex samples containing phospholipids and salts. Waters positioned this system as a tool to provide highly precise and flexible solutions, aiming to reduce downtime and improve laboratory productivity by helping clinical laboratories develop reliable methods for complex analytes across women's health, cancer assessment, and toxicology.
Full Take
The narrative emphasizes a progression from established high performance to demonstrable, clinically relevant sensitivity and stability in complex matrices. The core move is positioning the technology not just as an incremental improvement, but as a fundamental shift in reliability for diagnostic testing. The emphasis on trace-level performance for analytes like estradiol and hair toxicology suggests that the barrier for many critical clinical measurements lies not just in raw detection limits but in the consistency and stability of results when facing highly complex biological matrices.
The introduction of the StepWave™ XR Ion Guide, which extends ion ratio consistency by a factor of six, speaks to addressing a long-standing practical challenge in LC-MS/MS: managing signal variation in complex samples. This moves the discussion from instrument capability to operational assurance. The perspective from Cansford Laboratories suggests that enhanced signal stability and sensitivity directly translate into greater laboratory confidence when operating near critical decision cut-offs.
The implication is that diagnostic applications are increasingly bottlenecked by analytical variability rather than raw instrument ceiling performance. The pattern suggests an industry shift where incremental technological gains in instrumentation must be translated directly into quantifiable improvements in clinical workflow efficiency and risk mitigation. The underlying assumption is that increased robustness allows laboratories to pursue higher-stakes, lower-concentration measurements with greater assurance, which places responsibility on the technology provider to deliver proven consistency rather than just peak performance figures.
What further testing exists regarding whether this enhanced robustness translates equally across diverse sample types or if the stability improvements are highly dependent on the specific matrix components being analyzed? Does the focus on high sensitivity implicitly de-emphasize any potential trade-offs in method development complexity for the end-user laboratory technician? How does the market perceive the cost-benefit ratio of achieving six times longer ion ratio consistency versus simpler, less robust systems?
Sentinel — Human
The text reads like a legitimate press release or industry update, characterized by specific technical detail and quoted stakeholder perspectives, suggesting human authorship based on industry knowledge.